Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Carvedilol

AEMPS

Alpha and beta blocker (non-selective β + α1)

ATC code: C07AG02

Brand names: Coreg CR, Coreg

Updated · Methodology

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Anti-aging and longevity

Not recommended

Carvedilol is a nonselective β-adrenergic blocker with additional α1-blocking activity. It is prescribed for heart failure, after myocardial infarction, and for hypertension ( 2023, SEH-LELHA, 2017). In anti-aging regimens, carvedilol is positioned as a combined α/β-blocker for anti-aging of the vascular system in healthy normotensives. In people with normal blood pressure and no heart failure, no clinical studies of prophylactic use exist. The drug causes pronounced orthostatic hypotension (especially at start of treatment, with fall risk in older adults), bradycardia, fatigue, and hypoglycemia in patients with diabetes. If carvedilol was prescribed to a healthy person, consider seeking a second opinion.

Sources

  1. AEMPS: Ficha técnica de Carvedilol (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Blocks β1, β2 (non-selective) + α1 adrenoreceptors. Reduces HR and contractility + vasodilation (via α1 blockade). Drug of choice for HFrEF (COMET, CAPRICORN evidence). CYP2D6 + CYP2C9 metabolism.

Safety

Contraindications

  • Hypersensitivity to carvedilol
  • Decompensated heart failure
  • 2nd–3rd degree AV block without pacemaker
  • Severe bradycardia (<50 bpm)
  • Severe hepatic impairment
  • Bronchial asthma

Serious adverse effects

  • Heart failure decompensation at therapy initiation
  • Severe bronchospasm
  • AV block
  • Masking of hypoglycaemia in patients with diabetes

Common adverse effects

  • Dizziness and orthostatic hypotension
  • Fatigue
  • Bradycardia
  • Lower-extremity oedema
  • Hyperglycaemia in patients with diabetes

Pregnancy: can you take Carvedilol?

AEMPS summary of product characteristics (section 4.6): carvedilol is not recommended during pregnancy; there is no adequate clinical experience in pregnant women, and animal studies have shown reproductive toxicity but no evidence of teratogenic effects, with the potential risk to humans unknown. Beta-blockers reduce placental perfusion, which can lead to intrauterine fetal death, preterm delivery and immature fetuses, and the fetus and newborn may have adverse effects, especially hypoglycaemia and bradycardia. After birth, the newborn has a higher risk of cardiac and pulmonary complications. Carvedilol should not be used in pregnancy unless the expected benefits clearly outweigh the potential risks.

Breastfeeding: can you take Carvedilol?

Compatible with caution. Hale L3. Human milk transfer data are limited; animal data show transfer. Infant bradycardia, hypotension and hypoglycaemia are possible; clinical monitoring is advised.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Drug–nutrient interactions

Grapefruit juice

A single 300 ml glass of grapefruit juice raised carvedilol exposure 1.2-fold in the study cited in the Coropres SmPC. The clinical relevance is unclear, but a rise can worsen slow pulse, dizziness on standing and tiredness. The SmPC advises avoiding grapefruit juice at least until the response to the dose is stable.

Source: AEMPS: Ficha técnica de Coropres 25 mg comprimidos (carvedilol) (2025)

Drug–drug interactions

12 pairs found. Sorted from critical to minor.

MajorAmiodaroneClass III antiarrhythmics (Vaughan Williams)

Mechanism

Additive bradycardia and QT effect from amiodarone, on top of carvedilol's negative chronotropy. Often used in heart failure with reduced ejection fraction and atrial fibrillation — an acceptable combination.

Symptoms

Bradycardia, dizziness, fatigue, near-syncope. QT prolongation on ECG. Dizziness, syncope, palpitations. Rarely: polymorphic ventricular tachycardia (torsades de pointes). Risk is higher with hypokalaemia, hypomagnesaemia, bradycardia, and ischaemic heart disease.

Management

The AEMPS label for carvedilol lists amiodarone among the drugs that raise the risk of atrioventricular conduction disturbances. Start carvedilol at minimum dose (3.125 mg twice daily) with up-titration every 2 weeks. Check ECG and heart rate at 1 and 4 weeks. If heart rate falls below 50 bpm or 2nd/3rd-degree AV block develops, adjust both. Keep potassium and magnesium in the upper half of normal range.

Sources

Pair details →Amiodarone →

MajorClonidineCentral α2-adrenergic agonist

Mechanism

Clonidine is an α2-agonist that reduces sympathetic tone. Carvedilol blocks β-receptors plus α1-receptors. On abrupt clonidine withdrawal, the α2 effect is lost while carvedilol's β-blockade persists – an 'unopposed' α1 effect develops with a sharp blood pressure rise.

Symptoms

Abrupt clonidine withdrawal causes hypertensive crisis: sharp blood pressure rise, headache, tachycardia, anxiety, sweating. Symptoms appear 18–24 hours after a missed clonidine dose.

Management

For planned clonidine withdrawal, stop carvedilol 3–7 days beforehand, then taper clonidine over 1–2 weeks. Alternative antihypertensive therapy: an ACE-I (enalapril) plus a calcium channel blocker (amlodipine) without clonidine.

Sources

Pair details →Clonidine →

MajorColchicineAntigout agents

Mechanism

Carvedilol is a moderate P-glycoprotein inhibitor; colchicine is a P-glycoprotein substrate with a narrow therapeutic window. Colchicine plasma levels rise; myelosuppression and neuromyopathy risk.

Symptoms

Profuse diarrhoea, vomiting, abdominal pain. With prolonged combination: muscle weakness, peripheral neuropathy, falling leukocytes and platelets.

Management

In chronic kidney disease or hepatic impairment, the combination is not prescribed. With preserved function, colchicine 0.3 mg every other day for no more than 5 days. Alternative for gout: intra-articular glucocorticoid.

Sources

Pair details →Colchicine →

MajorDiltiazemCalcium channel blocker, non-DHP (benzothiazepine derivative)

Mechanism

Non-dihydropyridine calcium channel blocker (diltiazem) + beta-blocker (carvedilol) – additive AV node blockade and negative inotropic effect. Carvedilol's α1-blockade amplifies hypotension.

Symptoms

Bradycardia (heart rate below 50/min), dizziness, syncope. ECG: first- to second-degree AV block. Older patients: fall risk.

Management

Avoid the combination. Alternative for combined heart failure and angina: carvedilol + amlodipine (dihydropyridine, no AV effect) or diltiazem with carvedilol withdrawn.

Sources

Pair details →Diltiazem →

MajorFluoxetineSelective serotonin reuptake inhibitors

Mechanism

Fluoxetine is a potent CYP2D6 inhibitor, the main carvedilol metabolic route. Carvedilol plasma levels rise 2- to 3-fold. Marked hypotension and bradycardia emerge.

Symptoms

Bradycardia (heart rate below 50/min), dizziness, syncope. ECG: first- to second-degree AV block. Older patients: fall risk.

Management

Halve the carvedilol dose when combined; monitor blood pressure and pulse. Alternative beta-blockers without CYP2D6 dependence: bisoprolol or nebivolol. Alternative antidepressants without CYP2D6 inhibition: sertraline or escitalopram.

Sources

Pair details →Fluoxetine →

MajorTheophyllineMethylxanthine

Mechanism

Carvedilol blocks β2-adrenergic receptors (non-selective beta-blocker) and causes bronchoconstriction in asthma or COPD. Theophylline becomes less effective in these conditions.

Symptoms

Recurrence of asthma or COPD symptoms: dyspnoea, wheezing, need for additional short-acting β2-agonist doses. In severe asthma: risk of severe bronchospasm.

Management

Avoid the combination in asthma and severe COPD. In heart failure with mild COPD, a selective beta-blocker (bisoprolol, metoprolol) is preferred. Alternative to theophylline: long-acting inhaled β2-agonists with anticholinergics.

Sources

Pair details →Theophylline →

MajorVerapamilNon-dihydropyridine calcium channel blocker

Mechanism

Non-dihydropyridine calcium channel blocker (verapamil) + beta-blocker (carvedilol) – additive AV node blockade and negative inotropic effect. Carvedilol has additional α1-blockade, amplifying hypotension.

Symptoms

Bradycardia (heart rate below 50/min), dizziness, syncope. ECG: first- to second-degree AV block. Older patients: fall risk.

Management

Avoid the combination. For atrial fibrillation rate control, choose carvedilol + digoxin (instead of verapamil), or verapamil with carvedilol withdrawn. In heart failure, carvedilol is preferred (benefit proven in COPERNICUS and CIBIS).

Sources

Pair details →Verapamil →

ModerateAlprazolamBenzodiazepines. Short-to-medium-acting anxiolytics

Mechanism

Additive hypotension and sedation. Carvedilol's α/β-blockade causes fatigue and dizziness on its own; alprazolam adds GABAergic CNS depression.

Symptoms

Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk. Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk.

Management

On starting the combination, begin alprazolam at the minimum dose (0.25 mg at bedtime). In older patients, cap at 0.5 mg/day. Check standing/sitting BP at one week. With pronounced sedation, consider non-drug options for anxiety (CBT, breathing exercises) or switch to buspirone (no sedation).

Sources

Pair details →Alprazolam →

ModerateAmitriptylineTricyclic antidepressants (TCA)

Mechanism

TCA blocks α1-adrenoceptors — additive orthostatic hypotension with carvedilol (α/β-blocker). Amitriptyline's additive bradycardia and QT effect intensify as heart rate drops with carvedilol.

Symptoms

Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk.

Management

On starting the combination, begin amitriptyline at 10 mg at bedtime. In older patients, do not exceed 25 mg/day. Check standing/sitting BP, heart rate, and ECG at 2 weeks. For neuropathic pain, alternatives: gabapentin or pregabalin. For depression: sertraline or escitalopram (minimal cardiovascular effect).

Sources

Pair details →Amitriptyline →

ModerateAmlodipineCalcium channel blockers (dihydropyridines)

Mechanism

Additive hypotension and peripheral oedema. Amlodipine causes ankle oedema; the beta-blocker (carvedilol) may potentiate fluid retention.

Symptoms

Lower-leg and ankle oedema, weight gain. Hypotension and dizziness on standing. Worsening dyspnoea in heart failure patients.

Management

Standard combination in ischaemic heart disease with hypertension. In heart failure with reduced ejection fraction, titrate carefully and monitor weight and dyspnoea. For marked ankle oedema: switch to lercanidipine (less oedema among dihydropyridines).

Sources

Pair details →Amlodipine →

ModerateBudesonideInhaled corticosteroids (ICS)

Mechanism

Systemic budesonide retains sodium and water, blunting the beta-blocker's antihypertensive effect. Inhaled budesonide does not clinically affect BP.

Symptoms

On long-term systemic therapy: return or rise of blood pressure, leg oedema.

Management

For short systemic budesonide courses, no specific adjustment needed. For long-term therapy, check BP weekly in the first month. If BP rises, increase carvedilol or add an ACE inhibitor. Inhaled budesonide with carvedilol is unproblematic.

Sources

Pair details →Budesonide →

ModerateInsulinInsulins and analogues (general card; individual products require separate cards)

Mechanism

Beta-blockers mask adrenergic hypoglycaemia symptoms (tachycardia, tremor, sweating). In diabetics on insulin, the risk of severe unrecognised hypoglycaemia rises.

Symptoms

Confusion, vision changes, loss of contact, seizures. Tachycardia, tremor, and sweating are suppressed — the patient misses the hypoglycaemia.

Management

Prescribe carvedilol cautiously in diabetes. In heart failure with reduced ejection fraction, carvedilol remains first-line (improves survival) — teach the patient to recognise hypoglycaemia by any unusual sensation. On insulin, intensify glucose self-monitoring (4 times daily) for the first month. For hypertension without heart failure, alternatives: ACE inhibitor or ARB with a diuretic.

Sources

Pair details →Insulin →

Label mentions43 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • MajorAmiodarone
    «En combinación con carvedilol, se puede aumentar el riesgo de alteraciones en la conducción auriculoventricular. Al administrar carvedilol y diltiazem conjuntamente por vía oral, se han observado…»

    AEMPS, section 4.5 · Open on CIMA

  • Majorantiarrítmicosclass named in the label
    «En combinación con carvedilol, se puede aumentar el riesgo de alteraciones en la conducción auriculoventricular. Al administrar carvedilol y diltiazem conjuntamente por vía oral, se han observado…»

    AEMPS, section 4.5 · Open on CIMA

  • MajorDiltiazem
    «En combinación con carvedilol, se puede aumentar el riesgo de alteraciones en la conducción auriculoventricular. Al administrar carvedilol y diltiazem conjuntamente por vía oral, se han observado…»

    AEMPS, section 4.5 · Open on CIMA

  • MajorVerapamil
    «En combinación con carvedilol, se puede aumentar el riesgo de alteraciones en la conducción auriculoventricular. Al administrar carvedilol y diltiazem conjuntamente por vía oral, se han observado…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateantidiabéticosclass named in the label
    «Diabetes: Se debe proceder con precaución al administrar carvedilol a pacientes con diabetes mellitus, puesto que el medicamento puede ir asociado a un empeoramiento del control de la glucosa en…»

    AEMPS, section 4.4 · Open on CIMA

  • ModerateCiclosporin
    «Ciclosporina y tacrolimus: En dos estudios de trasplante de riñón y corazón, los pacientes que recibieron ciclosporina vía oral experimentaron un incremento de la concentración plasmática de…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateClonidine
    «Clonidina: La administración concomitante de clonidina con medicamentos con propiedades β-bloqueantes, puede aumentar la presión sanguínea y disminuir el ritmo cardiaco.»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateClonidine
    «Hypotensive Agents: Concomitant administration of clonidine with a β-blocker may cause hypotension and bradycardia. When concomitant treatment with a β-blocker and clonidine is to be terminated, the…»

    FDA, section 7 · Open on DailyMed

  • Moderatedigitálicosclass named in the label
    «Insuficiencia cardiaca congestiva crónica: En pacientes con insuficiencia cardiaca congestiva, la insuficiencia cardiaca o la retención de líquidos puede empeorar durante el aumento de la dosis de…»

    AEMPS, section 4.4 · Open on CIMA

  • Moderatedigitalisclass named in the label
    «Digitalis Glycosides: Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Digoxin concentrations…»

    FDA, section 7 · Open on DailyMed

  • ModerateDigoxin
    «Digoxina: En algunos estudios se ha demostrado un aumento en la exposición de digoxina de hasta el 20% en voluntarios sanos y en pacientes con insuficiencia cardiaca. Se ha observado un efecto…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateDigoxin
    «Digitalis Glycosides: Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Digoxin concentrations…»

    FDA, section 7 · Open on DailyMed

  • ModerateDiltiazem
    «Calcium Channel Blockers: Conduction disturbance (rarely with hemodynamic compromise) has been observed when COREG is coadministered with diltiazem. As with other β-blockers, if COREG is administered…»

    FDA, section 7 · Open on DailyMed

  • Moderateinsulinclass named in the label
    «Insulin or Oral Hypoglycemics: β-blockers may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular…»

    FDA, section 7 · Open on DailyMed

  • ModerateInsulin
    «Insulina y antidiabéticos orales: Se pueden ver potenciados los efectos de la insulina o de los hipoglucemiantes orales. Los signos y los síntomas de una hipoglucemia pueden estar enmascarados o…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateTacrolimus
    «Ciclosporina y tacrolimus: En dos estudios de trasplante de riñón y corazón, los pacientes que recibieron ciclosporina vía oral experimentaron un incremento de la concentración plasmática de…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateVerapamil
    «Calcium Channel Blockers: Conduction disturbance (rarely with hemodynamic compromise) has been observed when COREG is coadministered with diltiazem. As with other β-blockers, if COREG is administered…»

    FDA, section 7 · Open on DailyMed

  • MinorFluoxetine
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

  • AINEclass named in the label
    «Antiinflamatorios no esteroideos (AINE): El uso conjunto de AINEs y bloqueantes β adrenérgicos puede producir un incremento en la presión sanguínea y un empeoramiento en el control de la presión…»

    AEMPS, section 4.5 · Open on CIMA

  • Amiodarone
    «DRUG INTERACTIONS: Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction. ( 7.6 )»

    FDA, section 7 · Open on DailyMed

  • antagonistas del calcio no dihidropiridínicosclass named in the label
    «Bloqueantes de canales de calcio no dihidropiridínicos: amiodarona u otros antiarrítmicos»

    AEMPS, section 4.5 · Open on CIMA

  • antidiabéticos oralesclass named in the label
    «Insulina y antidiabéticos orales: Se pueden ver potenciados los efectos de la insulina o de los hipoglucemiantes orales. Los signos y los síntomas de una hipoglucemia pueden estar enmascarados o…»

    AEMPS, section 4.5 · Open on CIMA

  • CYP2C9 inhibitorsclass named in the label
    «Amiodarone: Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical…»

    FDA, section 7 · Open on DailyMed

  • CYP2D6 inhibitorsclass named in the label
    «CYP2D6 Inhibitors and Poor Metabolizers: Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but…»

    FDA, section 7 · Open on DailyMed

  • Fluconazole
    «Amiodarone: Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical…»

    FDA, section 7 · Open on DailyMed

  • Fluoxetine
    «CYP2D6 Inhibitors and Poor Metabolizers: Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but…»

    FDA, section 7 · Open on DailyMed

  • IMAOclass named in the label
    «Depresores de Catecolaminas: En pacientes que toman concomitantemente medicamentos con propiedades beta-bloqueantes y fármacos depresores de catecolaminas (p.e. reserpina, y los inhibidores de la…»

    AEMPS, section 4.5 · Open on CIMA

  • inhibidores del CYP2D6class named in the label
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

  • insulinaclass named in the label
    «Insulina y antidiabéticos orales: Se pueden ver potenciados los efectos de la insulina o de los hipoglucemiantes orales. Los signos y los síntomas de una hipoglucemia pueden estar enmascarados o…»

    AEMPS, section 4.5 · Open on CIMA

  • ISRSclass named in the label
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

  • MAO inhibitorsclass named in the label
    «Hypotensive Agents: Patients taking a β-blocker and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension…»

    FDA, section 7 · Open on DailyMed

  • Paroxetine
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

  • Paroxetine
    «CYP2D6 Inhibitors and Poor Metabolizers: Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but…»

    FDA, section 7 · Open on DailyMed

  • Propafenone
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

  • Propafenone
    «CYP2D6 Inhibitors and Poor Metabolizers: Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but…»

    FDA, section 7 · Open on DailyMed

  • Quinidine
    «Fluoxetina y paroxetina: Inhibidores del CYP2D6, tales como los inhibidores selectivos de la recaptación de serotonina, fluoxetina y paroxetina, o los antiarrítmicos quinidina o propafenona, pueden…»

    AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

  • MajorDarunavir
    «Established and Other Potentially Significant Drug Interactions: β-Blockers : e.g. carvedilol, metoprolol, timolol ­  beta-blockers Clinical monitoring of patients is recommended. A dose decrease…»

    FDA, section 7 · Open on DailyMed

  • ModerateCobicistat
    «Established and Other Potentially Significant Interactions: Beta-Blockers: e.g., metoprolol carvedilol timolol ↑ beta-blockers Clinical monitoring is recommended for coadministration with…»

    FDA, section 7 · Open on DailyMed

  • ModerateDarunavir
    «β-BLOQUEANTES: Carvedilol Metoprolol Timolol»

    AEMPS, section 4.5 · Open on CIMA

  • Digoxin
    «Pharmacokinetic Drug Interactions: Carvedilol 16% 14%»

    FDA, section 7 · Open on DailyMed

Showing 40 of 43, heaviest first

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Carvedilol used for?

Carvedilol is evaluated for the following indications with varying evidence strength: Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Carvedilol?

Common side effects of Carvedilol (≥ 1 in 100): Dizziness and orthostatic hypotension, Fatigue, Bradycardia, Lower-extremity oedema, Hyperglycaemia in patients with diabetes. See the Safety section for uncommon and serious reactions.

Is Carvedilol safe during pregnancy?

AEMPS summary of product characteristics (section 4.6): carvedilol is not recommended during pregnancy; there is no adequate clinical experience in pregnant women, and animal studies have shown reproductive toxicity but no evidence of teratogenic effects, with the potential risk to humans unknown. Beta-blockers reduce placental perfusion, which can lead to intrauterine fetal death, preterm delivery and immature fetuses, and the fetus and newborn may have adverse effects, especially hypoglycaemia and bradycardia. After birth, the newborn has a higher risk of cardiac and pulmonary complications. Carvedilol should not be used in pregnancy unless the expected benefits clearly outweigh the potential risks.

Is Carvedilol compatible with breastfeeding?

Compatible with caution. Hale L3. Human milk transfer data are limited; animal data show transfer. Infant bradycardia, hypotension and hypoglycaemia are possible; clinical monitoring is advised.

Who should not take Carvedilol?

Carvedilol is contraindicated in: Hypersensitivity to carvedilol; Decompensated heart failure; 2nd–3rd degree AV block without pacemaker; Severe bradycardia (<50 bpm); Severe hepatic impairment. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Atenolol, Bisoprolol, Labetalol, Metoprolol, Nebivolol, Propranolol, Sotalol